CTEP 10590, NORM: Nodular lymphocyte predominant Hodgkin lymphoma patients treated in a randomized phase II trial with either rituximab or mosunetuzumab Meeting Abstract
| Authors: | Steiner, R.; Bock, A. M.; Herrera, A. F.; Zulfa, O.; Hoffmann, M.; Ibrahimi, S.; Galanina, N.; Lee, H. J.; Green, M.; Lin, R.; Pinnix, C. C.; Moskowitz, A.; Yahalom, J.; Chihara, D. |
| Abstract Title: | CTEP 10590, NORM: Nodular lymphocyte predominant Hodgkin lymphoma patients treated in a randomized phase II trial with either rituximab or mosunetuzumab |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 44342 |
| Language: | English |
| ACCESSION: | WOS:001410587900048 |
| DOI: | 10.1182/blood-2024-202516 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
